Sanjiv Dhingra

List of Publications by Year
in descending order

77 papers	2,056 citations	201385 27 h-index	253896 43 g-index
77 all docs	77 docs citations	77 times ranked	3631 citing authors

#	Article	IF	Citations
1	Conversion of 2D MXene to Multiâ€Lowâ€Dimensional GerMXene Superlattice Heterostructure. Advanced Functional Materials, 2022, 32, 2108495.	7.8	9
2	An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning Î²-cell survival and cardiovascular conditions in diabetic patients. Molecular and Cellular Biochemistry, 2022, 477, 1681-1695.	1.4	15
3	Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases. Science Advances, 2022, 8, eabl4370.	4.7	13
4	The role of autophagy in the metabolism and differentiation of stem cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166412.	1.8	18
5	Editorial: The Analysis of Nanovesicles, Biomaterials and Chemical Compounds: Assisting the Promotion of Angiogenesis and Enhancing Tissue Engineering Strategies. Frontiers in Cardiovascular Medicine, 2022, 9, 904738.	1.1	0
6	Establishment of a new human iPSC cell line (UOMi007-A) from a patient with Hypophosphatasia. Stem Cell Research, 2022, 63, 102839.	0.3	0
7	MXene-aromatic thermosetting copolyester nanocomposite as an extremely wear-resistant biocompatible implant material for osteoarthritis applications. Applied Surface Science, 2022, 600, 154124.	3.1	12
8	Role of prostaglandin E2 in allogeneic mesenchymal stem cell therapy for cardiac repair. Canadian Journal of Physiology and Pharmacology, 2021, 99, 140-150.	0.7	0
9	Reduced Granule Cell Proliferation and Molecular Dysregulation in the Cerebellum of Lysosomal Acid Phosphatase 2 (ACP2) Mutant Mice. International Journal of Molecular Sciences, 2021, 22, 2994.	1.8	6
10	Generation and Evaluation of Isogenic iPSC as a Source of Cell Replacement Therapies in Patients with Kearns Sayre Syndrome. Cells, 2021, 10, 568.	1.8	11
11	Metformin impairs homing ability and efficacy of mesenchymal stem cells for cardiac repair in streptozotocin-induced diabetic cardiomyopathy in rats. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H1290-H1302.	1.5	23
12	Human induced pluripotent stem cell (hiPSC) line UOMi006-A derived from PBMCs of a patient with Kearns-Sayre syndrome. Stem Cell Research, 2021, 53, 102355.	0.3	0
13	Development of Fluorineâ€Free Tantalum Carbide MXene Hybrid Structure as a Biocompatible Material for Supercapacitor Electrodes. Advanced Functional Materials, 2021, 31, 2100015.	7.8	58
14	Generation of human induced pluripotent stem cell (hiPSC) line UOMi005-A from PBMCs of a patient with Kearns-Sayre syndrome. Stem Cell Research, 2021, 53, 102283.	0.3	5
15	Biocompatible Electrodes: Development of Fluorineâ€Free Tantalum Carbide MXene Hybrid Structure as a Biocompatible Material for Supercapacitor Electrodes (Adv. Funct. Mater. 30/2021). Advanced Functional Materials, 2021, 31, 2170219.	7.8	0
16	Carbon nanomaterials for cardiovascular theranostics: Promises and challenges. Bioactive Materials, 2021, 6, 2261-2280.	8.6	42
17	Fabrication of Smart Tantalum Carbide MXene Quantum Dots with Intrinsic Immunomodulatory Properties for Treatment of Allograft Vasculopathy. Advanced Functional Materials, 2021, 31, 2106786.	7.8	42
18	Fabrication of Smart Tantalum Carbide MXene Quantum Dots with Intrinsic Immunomodulatory Properties for Treatment of Allograft Vasculopathy (Adv. Funct. Mater. 46/2021). Advanced Functional Materials, 2021, 31, 2170341.	7.8	1

#	Article	IF	Citations
19	Sweet-MXene hydrogel with mixed-dimensional components for biomedical applications. Journal of the Mechanical Behavior of Biomedical Materials, 2020, 101, 103440.	1.5	43
20	Bioactive and trackable MXene quantum dots for subcellular nanomedicine applications. Materials and Design, 2020, 196, 109091.	3.3	37
21	Generation of human induced pluripotent stem cell (hiPSC) line UOMi001-A from a patient with Leigh-like syndrome harbouring compound heterozygous variants in ECHS1 gene. Stem Cell Research, 2020, 48, 101934.	0.3	3
22	Establishment of variant free-iPSC (UOMi003-A) line from patient with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. Stem Cell Research, 2020, 48, 101935.	0.3	0
23	Hypoxiaâ€induced increase in Sug1 leads to poor postâ€transplantation survival of allogeneic mesenchymal stem cells. FASEB Journal, 2020, 34, 12860-12876.	0.2	10
24	Hypoxiaâ€induced downregulation of cyclooxygenase 2 leads to the loss of immunoprivilege of allogeneic mesenchymal stem cells. FASEB Journal, 2020, 34, 15236-15251.	0.2	10
25	Induced pluripotent stem cell line UOMi002-A from a patient with Leigh syndrome with compound heterozygous mutations in the NDUFV1 gene. Stem Cell Research, 2020, 48, 101964.	0.3	8
26	Hypoxia-induced shift in the phenotype of proteasome from 26S toward immunoproteasome triggers loss of immunoprivilege of mesenchymal stem cells. Cell Death and Disease, 2020, 11, 419.	2.7	15
27	Allogeneic stem cell therapy for cardiac repair and host immune response. FASEB Journal, 2020, 34, 1-1.	0.2	0
28	Quantum Dots: Application of Ti₃C₂ MXene Quantum Dots for Immunomodulation and Regenerative Medicine (Adv. Healthcare Mater. 16/2019). Advanced Healthcare Materials, 2019, 8, 1970067.	3.9	8
29	Application of Ti₃C₂ MXene Quantum Dots for Immunomodulation and Regenerative Medicine. Advanced Healthcare Materials, 2019, 8, e1900569.	3.9	125
30	Introduction. Canadian Journal of Physiology and Pharmacology, 2019, 97, v-v.	0.7	0
31	Inflammation in myocardial injury: mesenchymal stem cells as potential immunomodulators. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H213-H225.	1.5	33
32	Influenza a virus-triggered autophagy decreases the pluripotency of human-induced pluripotent stem cells. Cell Death and Disease, 2019, 10, 337.	2.7	19
33	Hypoxia-induced 26S proteasome dysfunction increases immunogenicity of mesenchymal stem cells. Cell Death and Disease, 2019, 10, 90.	2.7	27
34	Elimination or neutralization of endogenous high-molecular-weight FGF2 mitigates doxorubicin-induced cardiotoxicity. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H279-H288.	1.5	11
35	High throughput screening reveals no significant changes in protein synthesis, processing, and degradation machinery during passaging of mesenchymal stem cells. Canadian Journal of Physiology and Pharmacology, 2019, 97, 536-543.	0.7	5
36	Application of injectable hydrogels for cardiac stem cell therapy and tissue engineering. Reviews in Cardiovascular Medicine, 2019, 20, 221.	0.5	25

#	Article	IF	Citations
37	Hypoxiaâ€induced Inactivation of 26S Proteasome Increases Immunogenicity of Allogeneic Mesenchymal Stem Cells. FASEB Journal, 2019, 33, lb600.	0.2	0
38	Myocardial Cell Signaling During the Transition to Heart Failure. , 2018, 9, 75-125.		12
39	iPSC based multisystemic-disease models from patients of mitochondrial disorder display varied disease progression in different cell types. Journal of Molecular and Cellular Cardiology, 2018, 124, 103.	0.9	0
40	Graphene Oxide-Gold Nanosheets Containing Chitosan Scaffold Improves Ventricular Contractility and Function After Implantation into Infarcted Heart. Scientific Reports, 2018, 8, 15069.	1.6	82
41	Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior. Stem Cell Research and Therapy, 2018, 9, 121.	2.4	29
42	Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells as an Individual-Specific and Renewable Source of Adult Stem Cells. Methods in Molecular Biology, 2017, 1553, 183-190.	0.4	3
43	Methods for Long-Term Storage of Murine Bone Marrow-Derived Mesenchymal Stem Cells. Methods in Molecular Biology, 2017, 1553, 241-248.	0.4	0
44	Derivation of Mesenchymal Stem Cells from Embryonic Stem Cells: A Non-Variable and Inexhaustive Source of Adult Stem Cells. Methods in Molecular Biology, 2017, 1553, 15-23.	0.4	0
45	Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity. PLoS ONE, 2017, 12, e0181535.	1.1	37
46	Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart. FASEB Journal, 2016, 30, 3069-3082.	0.2	29
47	Comparison of adipose tissue- and bone marrow- derived mesenchymal stem cells for alleviating doxorubicin-induced cardiac dysfunction in diabetic rats. Stem Cell Research and Therapy, 2015, 6, 148.	2.4	54
48	Modulation of Alloimmune Responses by Interleukin-10 Prevents Rejection of Implanted Allogeneic Smooth Muscle Cells and Restores Postinfarction Ventricular Function. Cell Transplantation, 2015, 24, 1013-1029.	1.2	3
49	Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy. European Heart Journal, 2015, 36, 2530-2540.	1.0	41
50	Stem cell therapy for cardiac regeneration: hits and misses. Canadian Journal of Physiology and Pharmacology, 2015, 93, 835-841.	0.7	10
51	Expression of CNPY2 in Mouse Tissues: Quantification and Localization. PLoS ONE, 2014, 9, e111370.	1.1	20
52	Synthesis of Aliphatic Polyester Hydrogel for Cardiac Tissue Engineering. Methods in Molecular Biology, 2014, 1181, 51-59.	0.4	5
53	Oleic acid mitigates TNF-Î±-induced oxidative stress in rat cardiomyocytes. Molecular and Cellular Biochemistry, 2013, 372, 75-82.	1.4	43
54	Interleukin-10 activates Toll-like receptor 4 and requires MyD88 for cardiomyocyte survival. Cytokine, 2013, 61, 304-314.	1.4	22

#	Article	IF	Citations
55	Preserving Prostaglandin E2 Level Prevents Rejection of Implanted Allogeneic Mesenchymal Stem Cells and Restores Postinfarction Ventricular Function. Circulation, 2013, 128, S69-78.	1.6	66
56	Interleukinâ€6 downregulation with mesenchymal stem cell differentiation results in loss of immunoprivilege. Journal of Cellular and Molecular Medicine, 2013, 17, 1136-1145.	1.6	39
57	Erythropoietin protects against doxorubicin-induced heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H2413-H2421.	1.5	32
58	Akt Regulates IL-10 Mediated Suppression of TNFÎ±-Induced Cardiomyocyte Apoptosis by Upregulating Stat3 Phosphorylation. PLoS ONE, 2011, 6, e25009.	1.1	52
59	Risk Factors Preceding Type 2 Diabetes and Cardiomyopathy. Journal of Cardiovascular Translational Research, 2010, 3, 580-596.	1.1	29
60	Challenges in Allogeneic Mesenchymal Stem Cellâ€"Mediated Cardiac Repair. Trends in Cardiovascular Medicine, 2010, 20, 263-268.	2.3	15
61	Targeting the Vicious Inflammationâ€"Oxidative Stress Cycle for the Management of Heart Failure. Antioxidants and Redox Signaling, 2010, 13, 1033-1049.	2.5	128
62	IL-10 attenuates TNF-Â-induced NFÂB pathway activation and cardiomyocyte apoptosis. Cardiovascular Research, 2009, 82, 59-66.	1.8	146
63	Biology of TNFÎ± and IL-10, and their imbalance in heart failure. Heart Failure Reviews, 2009, 14, 113-123.	1.7	69
64	A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicityThis article is one of a selection of papers published in a special issue celebrating the 125th anniversary of the Faculty of Medicine at the University of Manitoba.. Canadian Journal of Physiology and Pharmacology, 2009, 87, 756-763.	0.7	70
65	ANGIOTENSIN II INDUCED APOPTOSIS IN ADULT CARDIOMYOCYTE IS SUPPRESSED BY ALL TRANSâ€RETINOIC ACID. FASEB Journal, 2009, 23, 618.4.	0.2	0
66	ILâ€10 mitigates TNFâ€alpha induced cardiomyocyte apoptosis: Role of mitogenâ€activated protein kinases. FASEB Journal, 2008, 22, 758.18.	0.2	0
67	p38 and ERK1/2 MAPKs mediate the interplay of TNF-Î± and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3524-H3531.	1.5	108
68	Probucol promotes endogenous antioxidant reserve and confers protection against reperfusion injuryThis paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 439-443.	0.7	21
69	Transition from hypertrophy to heart failure in guinea pigs is associated with an increase in apoptosis. Journal of Molecular and Cellular Cardiology, 2007, 42, S84.	0.9	0
70	Interplay of TNF-Î± and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. Journal of Molecular and Cellular Cardiology, 2006, 41, 1023-1030.	0.9	108
71	Hypercholesterolemia and tissue-specific differential mRNA expression of type-1 5'-iodothyronine deiodinase under different selenium status in rats. Biological Research, 2006, 39, 307-19.	1.5	9
72	Hypercholesterolemia and LDL receptor mRNA expression: modulation by selenium supplementation. BioMetals, 2006, 19, 493-501.	1.8	32

#	Article	IF	Citations
73	Attenuation of LDL receptor gene expression by selenium deficiency during hypercholesterolemia. Molecular and Cellular Biochemistry, 2006, 282, 75-82.	1.4	27
74	Modulation of hypercholesterolemia-induced alterations in apolipoprotein B and HMG-CoA reductase expression by selenium supplementation. Chemico-Biological Interactions, 2006, 161, 49-56.	1.7	41
75	Hypercholesterolemia and apolipoprotein B expression: regulation by selenium status. Lipids in Health and Disease, 2005, 4, 28.	1.2	24
76	Effect of Selenium Depletion and Supplementation on the Kinetics of Type I 5'-Iodothyronine Deiodinase and T₃/T₄ in Rats. Biological Trace Element Research, 2004, 97, 95-104.	1.9	8
77	Protective role of selenium status on T3/T4 kinetics in rats under hyperlipidemia. Indian Journal of Biochemistry and Biophysics, 2003, 40, 260-4.	0.2	8